King Pharmaceuticals, established in 1994, is a vertically integrated branded pharmaceutical company that develops, manufactures and markets therapies and technologies primarily in specialty-driven markets including neuroscience hospital and acute care medicines. King has unique strengths in commercialization, advanced clinical development, manufacturing and regulatory affairs, which make the company a proven partner of choice for late stage compounds and novel branded prescription pharmaceutical products and technologies.
King Pharmaceuticals,® Inc. is a leader and partner of choice in bringing innovative, clinically differentiated pharmaceutical products and technologies to market.
King focuses on specialty-driven markets, which presently include:
NEUROSCIENCE (with an emphasis in Pain Management)
King Pharmaceuticals has a well-recognized and highly prescribed portfolio of core-marketed products. Our leading brands include Avinza® CII, a once-daily morphine treatment for chronic pain; Skelaxin®, for relief from discomfort associated with acute musculoskeletal conditions; Thrombin-JMI®, which aids in controlling bleeding during surgery; Altace®, an ACE inhibitor; Sonata® CIV, one of three approved non-benzodiazepine treatments for insomnia; Levoxyl®, for the treatment of thyroid disorders; and Meridian Auto injector Products/EpiPen®. read more »
Our unique strengths, resources and integrated capabilities make King a proven partner of choice. read more »
King Pharmaceuticals to Present at Leerink Swann Pain Roundtable Conference
Acurox™ Tablets Meet Primary Endpoint In Pivotal Phase III Study
Pain Therapeutics and King Pharmaceuticals Announce Submission Of New Drug Application for Remoxy™
King Pharmaceuticals Presentation at Leerink Swann Pain Roundtable Conference
King Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
©2000-2008 King Pharmaceuticals,® Inc. All rights reserved.
